Peptides regulate the immune response in cancer; this is important since, for example, beta-END favors the immune-mediated anticancer defenses [156,157], MET increases immunogenicity and recognition of cancer cells, blocks the formation of inflammatory cytokines and decreases immune checkpoints in colorectal cancer cells, and MET reduced immunosuppression in cutaneous squamous cell carcinoma. This evidence concerns the gene MET and cutaneous squamous cell carcinoma.